ImpriMed Research Update

Presentation Detail

Speaker
Sungwon Lim, PhD, CEO & Co-Founder of ImpriMed, Inc.

Synopsis
‍In this presentation, Dr. Sungwon Lim, CEO & Co-Founder of ImpriMed, shares the latest updates and new findings from ImpriMed. The key result includes that treatments predicted to be effective by ImpriMed’s artificial intelligence double the clinical response rate in relapsed B-cell lymphoma. Dr. Lim highlights successful cases that benefited from ImpriMed’s artificial intelligence-driven anticancer drug response predictions. ImpriMed’s flagship product, Personalized Prediction Profile, includes comprehensive diagnostic information and drug response predictions for canine blood cancers. ImpriMed’s artificial intelligence (AI) models, trained on real-world clinical outcome data, predict which anticancer drugs are most likely to be effective for a particular dog’s lymphoma or leukemia using the analytics of each patient’s live cancer cells.

Presentations

Boosting the power of AI-based treatment outcome predictions for canine lymphoma by combining tumor and germline genetic biomarkers and live-cell analytics

Veterinary Cancer Society Annual Conference 2024

ImpriMed Research Update

Presentation Detail

Presentations

Boosting the power of AI-based treatment outcome predictions for canine lymphoma by combining tumor and germline genetic biomarkers and live-cell analytics

Novel Genetic Biomarkers of Chemotherapeutic Response in Canine Lymphoma and Improved Predictive Power With Integration of Machine Learning

Decoding Feline Lymphoma: From Diagnosis to Prognosis

Improving Canine Lymphoma Treatment Outcomes by Individualizing Drug Selection using Machine-Learning-Based Predictive Models

Dramatically increased clinical remission rates and survival times in dogs with high-grade T-cell lymphoma and relapsed B-cell lymphoma in clinical study of AI decision support

Treatment-specific risk stratification of feline lymphoma based on unsupervised clustering of flow cytometry results

AI-driven Personalized Medicine for Cancer Care

Increased survival and remission rates in prospective study of relapsed B-cell lymphoma patients treated by oncologists using ImpriMed's AI predictions

Canine Lymphoma Diagnostics Past, Present and Future: How AI technology and genetics are pushing the boundaries in veterinary medicine

Impact of AI on clinical practice and outcome

Identification of drug response biomarkers for canine lymphoma in large-scale NGS screen

ImpriMed: AI-driven Personalized Medicine for Pet Cancer Care

Reinventing precision medicine: from dogs to humans

Identification of Novel Predictive Biomarkers of Anticancer Drug Responses in Canine B-Cell Lymphoma Using Targeted NGS

ImpriMed Research Update

Drugs predicted to be effective using artificial intelligence (AI) double the clinical response rate in canines with relapsed B-cell lymphoma

Precision medicine for pet cancer care

Predicting dynamic clinical outcomes of (L-)CHOP chemotherapy for canine lymphoma patients using an artificial intelligence model

ImpriMed: Experiences from the eyes of an oncologist in clinical practice

Predicting likelihood of in vivo chemotherapy response in canine lymphoma using ex vivo drug sensitivity and immunophenotyping data in a machine learning model

ImpriMed: A data-driven, personalized chemotherapy drug testing service for canine blood cancer patients

Individualizing chemotherapy for canine lymphoma based on ex vivo drug sensitivity test

From dog to human: precision medicine for comparative oncology

ImpriMed: precision medicine for pet cancer care

Individualizing chemotherapy for canine lymphoma based on ex vivo drug sensitivity test